JP2012509922A - 新規粉末化結晶質吸入薬 - Google Patents

新規粉末化結晶質吸入薬 Download PDF

Info

Publication number
JP2012509922A
JP2012509922A JP2011537951A JP2011537951A JP2012509922A JP 2012509922 A JP2012509922 A JP 2012509922A JP 2011537951 A JP2011537951 A JP 2011537951A JP 2011537951 A JP2011537951 A JP 2011537951A JP 2012509922 A JP2012509922 A JP 2012509922A
Authority
JP
Japan
Prior art keywords
amino
phenyl
dry gas
spray
forming agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509922A5 (enExample
Inventor
ヴァイラー，クラウディウス
エーゲン，マルク
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2012509922A publication Critical patent/JP2012509922A/ja
Publication of JP2012509922A5 publication Critical patent/JP2012509922A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011537951A 2008-11-27 2009-11-23 新規粉末化結晶質吸入薬 Pending JP2012509922A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170072.6 2008-11-27
EP08170072 2008-11-27
PCT/EP2009/065621 WO2010060875A1 (de) 2008-11-27 2009-11-23 Neue pulverförmige kristalline arzneimittel zur inhalation

Publications (2)

Publication Number Publication Date
JP2012509922A true JP2012509922A (ja) 2012-04-26
JP2012509922A5 JP2012509922A5 (enExample) 2013-01-17

Family

ID=40568782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537951A Pending JP2012509922A (ja) 2008-11-27 2009-11-23 新規粉末化結晶質吸入薬

Country Status (5)

Country Link
US (2) US20120135969A1 (enExample)
EP (1) EP2370053A1 (enExample)
JP (1) JP2012509922A (enExample)
CA (1) CA2744655A1 (enExample)
WO (1) WO2010060875A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527390A (ja) * 2012-09-06 2015-09-17 セルビオス − ファルマ・エス・アーＣｅｒｂｉｏｓ − Ｐｈａｒｍａｓａ チオトロピウム製剤
JP2017511323A (ja) * 2014-03-31 2017-04-20 ホビオネ インターナショナル エルティーディー 増強された特性を有する粉末を生産するための改良噴霧乾燥方法
JP2019519542A (ja) * 2016-06-30 2019-07-11 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子
JP2023540190A (ja) * 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177101A (ja) * 1982-04-09 1983-10-17 Lion Corp 熱風噴霧乾燥方法
JPS6411602A (en) * 1987-07-06 1989-01-17 Ogawara Kakoki Kk Spray dryer having fluidized bed therein
JPH0663301A (ja) * 1992-08-19 1994-03-08 Kao Corp 噴霧乾燥方法及び噴霧乾燥装置
JPH11503731A (ja) * 1995-04-14 1999-03-30 インヘイル セラピューティック システムズ エアゾール化医薬の肺への送達
JP2002529498A (ja) * 1998-11-13 2002-09-10 ヤゴ・リサーチ・アクチェンゲゼルシャフト 吸入用の乾燥粉末
JP2007503380A (ja) * 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 含水量を削減した長期安定性に優れた噴霧乾燥非晶質粉末
JP2007533683A (ja) * 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患治療用のベンゾオキサジン含有医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
AU3764199A (en) * 1998-04-29 1999-11-16 Genentech Inc. Spray dried formulations of igf-i
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
DE102004022926A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177101A (ja) * 1982-04-09 1983-10-17 Lion Corp 熱風噴霧乾燥方法
JPS6411602A (en) * 1987-07-06 1989-01-17 Ogawara Kakoki Kk Spray dryer having fluidized bed therein
JPH0663301A (ja) * 1992-08-19 1994-03-08 Kao Corp 噴霧乾燥方法及び噴霧乾燥装置
JPH11503731A (ja) * 1995-04-14 1999-03-30 インヘイル セラピューティック システムズ エアゾール化医薬の肺への送達
JP2002529498A (ja) * 1998-11-13 2002-09-10 ヤゴ・リサーチ・アクチェンゲゼルシャフト 吸入用の乾燥粉末
JP2007503380A (ja) * 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 含水量を削減した長期安定性に優れた噴霧乾燥非晶質粉末
JP2007533683A (ja) * 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患治療用のベンゾオキサジン含有医薬組成物

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527390A (ja) * 2012-09-06 2015-09-17 セルビオス − ファルマ・エス・アーＣｅｒｂｉｏｓ − Ｐｈａｒｍａｓａ チオトロピウム製剤
JP2017511323A (ja) * 2014-03-31 2017-04-20 ホビオネ インターナショナル エルティーディー 増強された特性を有する粉末を生産するための改良噴霧乾燥方法
US10463621B2 (en) 2014-03-31 2019-11-05 Hovione Holding Limited Spray drying process for production of powders with enhanced properties
US10918603B2 (en) 2014-03-31 2021-02-16 Hovione Holding Limited Spray drying process for production of powders with enhanced properties
JP2019519542A (ja) * 2016-06-30 2019-07-11 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子
US11458093B2 (en) 2016-06-30 2022-10-04 Philip Morris Products S.A. Nicotine particles
JP7471774B2 (ja) 2016-06-30 2024-04-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子
US12048762B2 (en) 2016-06-30 2024-07-30 Philip Morris Products S.A. Nicotine particles
JP2023540190A (ja) * 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物

Also Published As

Publication number Publication date
US20150258030A1 (en) 2015-09-17
WO2010060875A1 (de) 2010-06-03
EP2370053A1 (de) 2011-10-05
CA2744655A1 (en) 2010-06-03
US20120135969A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
US20150258030A1 (en) Novel powdered crystalline medicines for inhalation
RU2470680C2 (ru) Ингалятор
JP2009533114A (ja) 吸入器
JP2009538656A (ja) アトマイザ
US8518377B2 (en) Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
CA2629358A1 (en) Needle for puncturing powder capsules for inhalation
JP4903857B2 (ja) 医薬製剤の投与の為のエアロゾル製剤
JP5552118B2 (ja) 吸入用の新規な埋込み粒子
US7736628B2 (en) Powdered inhalants based on modified lactose mixtures as excipient
JP5522940B2 (ja) 微粒化方法
JP2011512175A (ja) カプセル充填方法及び装置
US20080279788A1 (en) Propellant for Dosing Aerosols Comprising Packagings
JP2009531238A (ja) 複数回投与粉末吸入器用の最適化した排出特性を有する包装手段
JP2011525177A (ja) 医薬品を製造するための新規なエマルション
HK1128651A (en) Dosage aerosols for the administration of pharmaceutical preparations
HK1128892A (en) Packaging means for multi-dose powder inhalers with optimized discharging properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141014